{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:06:16Z","timestamp":1771603576715,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jpba.2019.112858","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T11:50:54Z","timestamp":1567597854000},"page":"112858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Liquid chromatography-tandem mass spectrometric method for the quantification of eliglustat in rat plasma and the application in a pre-clinical study"],"prefix":"10.1016","volume":"177","author":[{"given":"Jingjing","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huidan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiufang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2019.112858_bib0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/path.3021","article-title":"The cellular pathology of lysosomal diseases","volume":"226","author":"Cox","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.jpba.2019.112858_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2019.112858_bib0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcmd.2017.01.006","article-title":"A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: evaluation of frequency, timing, and duration","volume":"68","author":"Peterschmitt","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.jpba.2019.112858_bib0020","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jpba.2019.112858_bib0025","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.24877","article-title":"Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: the phase 3 ENGAGE trial","volume":"92","author":"Mistry","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jpba.2019.112858_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ajh.25300","article-title":"Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: final results from the phase 2 trial","volume":"94","author":"Lukina","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jpba.2019.112858_bib0035","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13023-019-1085-6","article-title":"Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1","volume":"14","author":"Peterschmitt","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jpba.2019.112858_bib0040","doi-asserted-by":"crossref","DOI":"10.1093\/chromsci\/bmz033","article-title":"A bioanalytical method for eliglustat quantification in rat plasma","author":"Reddy","year":"2019","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2019.112858_bib0045","article-title":"UPLC-MS\/MS method for the quantification of ertugliflozin and sitagliptin in rat plasma","author":"Qiu","year":"2018","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jpba.2019.112858_bib0050","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jpba.2018.12.036","article-title":"UPLC-MS\/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma","volume":"166","author":"Xu","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.112858_bib0055","series-title":"Guidance for Industry; Bioanalytical Method Validation","author":"Center for Drug Evaluation and Research of the U.S. Department of Health and Human Services Food and Drug Administration","year":"2018"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519317480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519317480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:57:15Z","timestamp":1760000235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708519317480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":11,"alternative-id":["S0731708519317480"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.112858","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liquid chromatography-tandem mass spectrometric method for the quantification of eliglustat in rat plasma and the application in a pre-clinical study","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.112858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112858"}}